Vanda Pharmaceuticals Profit Margin

The latest profit margin for VNDA is -119.87% as of September 2026. That compares with -39.7% in the prior-year period — down 201.9% year over year. That is below the Healthcare sector average of 9.48%. Investors often review this figure alongside Vanda Pharmaceuticals's historical trend and sector peers before judging valuation or financial health.

Over the past year, VNDA's profit margin moved from -39.7% to -119.87% — a 201.9% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Vanda Pharmaceuticals's valuation or profitability profile.

Against Healthcare companies, VNDA currently prints -119.87% for profit margin, while the sector average sits near 9.48%. That is roughly 1364.3% below the sector mean. Large gaps often invite a closer look at Vanda Pharmaceuticals's growth, margins, and balance sheet.

Profit Margin shows how effectively Vanda Pharmaceuticals converts resources into returns. At -119.87%, VNDA may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with -39.7% in the prior-year period — down 201.9% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting VNDA's profit margin (-119.87%), review year-over-year change from -39.7%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.